| Overview |
| bs-0315R-FITC |
| FGL2 Polyclonal Antibody, FITC Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse, Rat |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from rat FGL2 |
| 75-150/422 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 84586 |
| G3V7P2 |
| Secreted |
| Fibroleukin; Cytotoxic T-lymphocyte-specic protein; Fibrinogen-like protein 2; Fibrinogen like protein 2; Prothrombinase; Fibroleukin; pT49; T49; G3V7P2_RAT, Fibrinogen-like 2. |
| FGL2 is a secreted protein that is similar to the beta- and gamma-chains of fibrinogen. The carboxyl-terminus of the encoded protein consists of the fibrinogen-related domains (FRED). The encoded protein forms a tetrameric complex which is stabilized by interchain disulfide bonds. It may play a role in physiologic functions at mucosal sites. It is constitutively expressed in cytotoxic T-cells. Lack of expression in other lymphoid- and nonlymphoid-derived cell lines suggested that expression of FGL2 may be restricted to lymphocytes. FGL2 is induced via a mechanism involving IFNG and components of the IFNG signaling pathway, including STAT1 and IRF1. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz